Independent and not affiliated with the FDA, MHRA, ISPE, PDA, or any agency. Get the appgoutham@madhadi.com
madhadi.comData Integrity & GxP Quality
Browse all topics → Articles Templates & Procedures Learning paths GlossaryScenariosToolsRegulatory ReferencesLearning PathsTopics About Start here
Checklist Plug-and-play starting point Audits & Inspection

Checklist: Health Authority Meeting Package (Briefing Book) Readiness

A plug-and-play readiness checklist for an FDA meeting package or EMA scientific-advice briefing document, covering structure, question quality, data support, and the quality and inspection statements that must be accurate, with a filled specimen.

Document type: Checklist

Read and copy the template below into your own quality system. It is a generic starting point for your own internal use, provided as is, with no warranty; see the Terms and License. Adopting it does not by itself create compliance.

This is a ready-to-use checklist. Work through each item before a meeting package or briefing document is released to a health authority. Mark each item Pass, Fail, or N/A, record the evidence location, and resolve every Fail before submission. A filled specimen follows. Verify package structure and timing against the current guidance for your meeting type.

How to use

  • Run this before the package is finalized, not after.
  • Any Fail blocks release until corrected or justified.
  • The reviewer signing the checklist is accountable that each Pass is real, not assumed.

Section A: Administrative and structure

#ItemPass / Fail / N/AEvidence / location
A1Cover / application information complete (product, IND/NDA/BLA/MAA number, meeting type, requested format, contacts)<<FILL>>
A2Meeting type matches the trigger and is stated correctly<<FILL>>
A3Package structure follows the current guidance for this meeting type<<FILL>>
A4Attendee list complete with names, titles, affiliations, and disciplines; requested agency disciplines stated<<FILL>>
A5Package within the page / format expectations; all cross-references resolve<<FILL>>
A6Submission deadline for this meeting type confirmed and met<<FILL>>

Section B: Product background

#ItemPass / Fail / N/AEvidence / location
B1Indication, mechanism, and development stage stated concisely<<FILL>>
B2Prior agency interactions and their outcomes summarized accurately<<FILL>>
B3Regulatory designations (fast track, breakthrough, orphan, RMAT, PRIME) stated correctly<<FILL>>

Section C: Question quality (the core)

#ItemPass / Fail / N/AEvidence / location
C1Questions grouped by discipline<<FILL>>
C2Each question states the issue and context briefly<<FILL>>
C3Each question gives the sponsor’s proposed approach and rationale<<FILL>>
C4Each question ends with a closed ask (“Does the Agency agree that X is acceptable to support Y?”), not an open one<<FILL>>
C5Questions are prioritized; the number is focused, not padded<<FILL>>
C6Each question cites the relevant standard / guidance where one applies<<FILL>>

Section D: Data support

#ItemPass / Fail / N/AEvidence / location
D1Each position is supported by the data referenced in the package<<FILL>>
D2Nonclinical, clinical, CMC, and statistical summaries are consistent with the source documents<<FILL>>
D3Tables and figures are accurate and self-explanatory<<FILL>>

Section E: Quality, validation, and inspection statements (must be true)

#ItemPass / Fail / N/AEvidence / location
E1Every statement about validation status is accurate and dated; nothing is overstated as “complete”<<FILL>>
E2Every statement about data integrity controls is accurate<<FILL>>
E3GMP / facility status and inspection history are stated accurately, including open observations<<FILL>>
E4Any quality-system commitment in the package is backed by a credible, dated plan<<FILL>>
E5QA has reviewed and signed off on sections E1 to E4<<FILL>>

Section F: Internal control

#ItemPass / Fail / N/AEvidence / location
F1All discipline sections reviewed by their SME owners<<FILL>>
F2Positions and fallback commitments approved per the internal approval matrix<<FILL>>
F3A single regulatory lead owns the package, agenda, and minutes<<FILL>>

Signoff

FieldEntry
Program / application<<FILL>>
Meeting type<<FILL>>
Total Fails open at review<<FILL: must be 0 at release>>
Reviewer (name, signature, date)<<FILL>>
QA reviewer (name, signature, date)<<FILL>>
Regulatory lead approval (name, signature, date)<<FILL>>

References

FDA Guidance for Industry, Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products (current revision). EMA procedural guidance on scientific advice and protocol assistance. ICH M4 (CTD / eCTD) for supporting-data structure.

Confirm current package structure and timing for your meeting type before relying on this checklist.


Filled specimen

The following shows Section C and the signoff completed for an example end-of-phase-2 (Type B(EOP)) package. Illustrative only.

#ItemPass / Fail / N/AEvidence / location
C1Questions grouped by disciplinePassClinical Q1-3, CMC Q4-5, Stats Q6
C2Each question states issue and contextPassBackground paragraph per question
C3Sponsor approach and rationale givenPassPosition stated per question
C4Closed askFail then PassQ4 originally “What are the Agency’s expectations for comparability”; rewritten to “Does the Agency agree the ICH Q5E comparability data support the site change without clinical bridging?”
C5Prioritized, focusedPass6 questions, milestone-relevant only
C6Cites relevant standardPassQ4 cites ICH Q5E; Q6 cites the SAP
FieldEntry
Program / applicationCompound X-19, end-of-phase-2, IND 142xxx
Meeting typeType B(EOP)
Total Fails open at release0 (Q4 corrected before submission)
ReviewerA. Lindgren, signed, 11 May 2026
QA reviewerR. Gomez, signed, 12 May 2026
Regulatory lead approvalJ. Okafor, signed, 12 May 2026

The single Fail caught here, an open-ended comparability question, is the most common package defect: it would have drawn a non-committal answer the sponsor could not use. Rewriting it to a closed ask is what made the meeting productive.

Common inspection findings this checklist prevents

  • A package that overstated validation or facility readiness, contradicted later at inspection.
  • Open-ended questions that produced advice the program could not rely on.
  • A package submitted late or incomplete, causing the meeting to be cancelled or rescheduled.

How to adapt this checklist

  1. Replace the package-structure expectations with those of the current guidance for your meeting type.
  2. Insert your internal approval matrix reference in F2.
  3. Add discipline-specific rows where your program has unusual content (for example a companion diagnostic or a combination product constituent).
Use madhadi.com as an app Full screen, works offline, one tap from your home screen.